ArticleJournal of Alzheimer's disease : JAD2010
Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma.
Article in Journal of Alzheimer's disease : JAD, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia.Scientific reports · 2022Article
- Graphene based electrochemical immunosensor for the ultra-sensitive label free detection of Alzheimer's beta amyloid peptides Aβ(1-42).Nanoscale advances · 2021Article
- Assessment of High Risk for Alzheimer's Disease Using Plasma Biomarkers in Subjects with Normal Cognition in Taiwan: A Preliminary Study.Journal of Alzheimer's disease reports · 2021Article
- Immunomagnetic Reduction Detects Plasma AβNeurology and therapy · 2020Review
- Human plasma biomarker responses to inhalational general anaesthesia without surgery.British journal of anaesthesia · 2020Article
- Association of plasma β-amyloid 40 and 42 concentration with type 2 diabetes among Chinese adults.Diabetologia · 2020Article
- Combining Select Blood-Based Biomarkers with Neuropsychological Assessment to Detect Mild Cognitive Impairment among Mexican Americans.Journal of Alzheimer's disease : JAD · 2020Article
- Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia.Dementia and geriatric cognitive disorders · 2020Article
- Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients.Frontiers in aging neuroscience · 2020Review
- A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma.Journal of Alzheimer's disease : JAD · 2020Article
- Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- A proteomic signature for dementia with Lewy bodies.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias.Proteomes · 2018Review
- A validated antibody panel for the characterization of tau post-translational modifications.Molecular neurodegeneration · 2017Article
- Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases.Scientific reports · 2017Article
- Exploring Biomarkers for Alzheimer's Disease.Journal of clinical and diagnostic research : JCDR · 2016Review
- Molecular markers of amnestic mild cognitive impairment among Mexican Americans.Journal of Alzheimer's disease : JAD · 2016Article
- Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker.Alzheimer's & dementia (Amsterdam, Netherlands) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Plasma amyloid-β (Aβ) level could be useful as a non-invasive biomarker in Alzheimer's disease research. We compared a multiplex electrochemiluminescence detection method with a well established ELISA method for plasma Aβ quantification. Compared to the ELISA method, the electrochemiluminescence detection method demonstrates a statistically significant, but modest correlation. The reasons for this may include the differences in the affinities of antibodies, and purity and source of Aβ peptides used as standards. However, the advantages of electrochemiluminescence detection technology include short processing time and small sample volume. This comparison demonstrates the need for a further study in optimizing this system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.